Latest News
Researchers have found a way to block a “master switch” in the eye and the brain that controls inflammation, introducing a possible target for combatting glaucoma and other neurodegenerative diseases.
On Friday, Oct. 13, BrightFocus and the International African American Museum hosted "Small Miracles: A Promise Toward a Future of Health and Wellness," an in-person and live-streamed panel discussion on the importance of equitable access to health care.
An updated drug shows promise in treating traumatic brain injuries that can lead to neurodegenerative diseases.
Researchers have successfully demonstrated that hagfish slime proteins can accurately replicate membranes in the human eye.
A team of researchers including Alzheimer’s Disease Research grantee Eunhee Kim, PhD, have used a 3D brain cell culture model to show that the exercise-induced muscle hormone, irisin, reduces the level of amyloid beta associated with Alzheimer’s disease.
In This Issue:
- Using Cells for Potential New Treatments
- President’s Corner
- Beyond Eye Pressure: New Avenue of Research
- And More!
The FDA has approved a new dosing regimen for Eylea, an injectable drug to treat degenerative eye diseases such as wet age-related macular degeneration. This means people taking the drug may need these eye injections less frequently.
Global brain and vision research nonprofit BrightFocus Foundation has appointed three industry leaders to its board of directors.
Taking a unique approach to better diagnose and treat one of the world’s leading causes of blindness, a researcher from the University of Canberra in Australia has received a $500,000 boost for his three-year project, thanks to a grant from BrightFocus Foundation’s Macular Degeneration Research program.
A new study bridging neuroscience and machine learning offers insights into the potential role of astrocytes in the human brain.
